These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

603 related items for PubMed ID: 25341476

  • 21. Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: The Denosumab and Teriparatide Follow-up study (DATA-Follow-up).
    Leder BZ, Tsai JN, Jiang LA, Lee H.
    Bone; 2017 May; 98():54-58. PubMed ID: 28286299
    [Abstract] [Full Text] [Related]

  • 22. Effect of strontium ranelate on lumbar spine bone mineral density in women with established osteoporosis previously treated with teriparatide.
    Anastasilakis AD, Polyzos SA, Avramidis A, Papatheodorou A, Terpos E.
    Horm Metab Res; 2009 Jul; 41(7):559-62. PubMed ID: 19204890
    [Abstract] [Full Text] [Related]

  • 23. Combination therapy with parathyroid hormone analogs and antiresorptive agents for osteoporosis: a systematic review and meta-analysis of randomized controlled trials.
    Lou S, Lv H, Yin P, Li Z, Tang P, Wang Y.
    Osteoporos Int; 2019 Jan; 30(1):59-70. PubMed ID: 30539271
    [Abstract] [Full Text] [Related]

  • 24. Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial.
    Leder BZ, Tsai JN, Uihlein AV, Burnett-Bowie SA, Zhu Y, Foley K, Lee H, Neer RM.
    J Clin Endocrinol Metab; 2014 May; 99(5):1694-700. PubMed ID: 24517156
    [Abstract] [Full Text] [Related]

  • 25. Effects of bone remodeling agents following teriparatide treatment.
    Burkard D, Beckett T, Kourtjian E, Messingschlager C, Sipahi R, Padley M, Stubbart J.
    Osteoporos Int; 2018 Jun; 29(6):1351-1357. PubMed ID: 29541794
    [Abstract] [Full Text] [Related]

  • 26. Romosozumab and antiresorptive treatment: the importance of treatment sequence.
    Cosman F, Kendler DL, Langdahl BL, Leder BZ, Lewiecki EM, Miyauchi A, Rojeski M, McDermott M, Oates MK, Milmont CE, Libanati C, Ferrari S.
    Osteoporos Int; 2022 Jun; 33(6):1243-1256. PubMed ID: 35165774
    [Abstract] [Full Text] [Related]

  • 27. The use of combination therapy in the treatment of postmenopausal osteoporosis.
    Compston J.
    Endocrine; 2012 Feb; 41(1):11-8. PubMed ID: 22038453
    [Abstract] [Full Text] [Related]

  • 28. Commentary: Concurrent administration of PTH and antiresorptives: Additive effects or DXA cosmetics.
    Eriksen EF, Brown JP.
    Bone; 2016 May; 86():139-42. PubMed ID: 26944033
    [Abstract] [Full Text] [Related]

  • 29. Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab.
    Kendler DL, Bone HG, Massari F, Gielen E, Palacios S, Maddox J, Yan C, Yue S, Dinavahi RV, Libanati C, Grauer A.
    Osteoporos Int; 2019 Dec; 30(12):2437-2448. PubMed ID: 31628490
    [Abstract] [Full Text] [Related]

  • 30. Effects of four-year cyclic versus two-year daily teriparatide treatment on volumetric bone density and bone strength in postmenopausal women with osteoporosis.
    Ganapathy A, Nieves JW, Keaveny TM, Cosman F.
    Bone; 2023 Feb; 167():116618. PubMed ID: 36410666
    [Abstract] [Full Text] [Related]

  • 31. Six months of parathyroid Hormone (1-84) administered concurrently versus sequentially with monthly ibandronate over two years: the PTH and ibandronate combination study (PICS) randomized trial.
    Schafer AL, Sellmeyer DE, Palermo L, Hietpas J, Eastell R, Shoback DM, Black DM.
    J Clin Endocrinol Metab; 2012 Oct; 97(10):3522-9. PubMed ID: 22791766
    [Abstract] [Full Text] [Related]

  • 32. Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis.
    Finkelstein JS, Wyland JJ, Lee H, Neer RM.
    J Clin Endocrinol Metab; 2010 Apr; 95(4):1838-45. PubMed ID: 20164296
    [Abstract] [Full Text] [Related]

  • 33. Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate.
    Brown JP, Roux C, Ho PR, Bolognese MA, Hall J, Bone HG, Bonnick S, van den Bergh JP, Ferreira I, Dakin P, Wagman RB, Recknor C.
    Osteoporos Int; 2014 Jul; 25(7):1953-61. PubMed ID: 24676847
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Combination/sequential therapies for anabolic and antiresorptive skeletal agents for osteoporosis.
    Bilezikian JP, Rubin MR.
    Curr Osteoporos Rep; 2006 Mar; 4(1):5-13. PubMed ID: 16527002
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 31.